Impedance Study of Alternative (La,Sr)FeO3-and (La,Sr)(Co,Fe)O3- MIEC Cathode Compositions

Leonide, A.; Meulenberg, W. A.; Ivers-Tiffée, E.; Weber, A.; Rüger, B.

doi:10.1149/1.3265473

Journal Article

Impedance Study of Alternative (La,Sr)FeO3-and (La,Sr)(Co,Fe)O3- MIEC Cathode Compositions

Leonide, A. ; Rüger, B. ; Weber, A. ; Meulenberg, W. A.FZJ* ; Ivers-Tiffée, E.

2010
Electrochemical Society Pennington, NJ

Journal of the Electrochemical Society 157, B234 - B239 (2010) [10.1149/1.3265473]

This record in other databases:

Please use a persistent id in citations: doi:10.1149/1.3265473

Abstract: This open-label extension evaluated the long-term efficacy and tolerability of rufinamide in patients with Lennox-Gastaut syndrome (LGS) who had previously completed a 12-week double-blind study.In total, 124 patients (aged 4-37 years), receiving 1-3 concomitant antiepileptic drugs, were treated with rufinamide approximately 25-60 mg/kg/day. Efficacy was assessed by seizure frequency; tolerability by adverse events (AEs) and laboratory tests.Overall, patients were treated with rufinamide for a median (range) of 432 (10-1149) days. Reductions in seizure frequency were observed throughout the study; during the last 12 months of treatment, 41.0% and 47.9% of patients had > or = 50% reduction in total and tonic-atonic seizure frequency, respectively. The most common AEs were vomiting (30.6%) and pyrexia (25.8%).In this open-label extension, rufinamide appeared to be an effective long-term adjunctive therapy for the treatment of LGS-associated seizures in children and young adults.

Keyword(s): cobalt compounds (auto) ; diffusion (auto) ; electrochemical electrodes (auto) ; electrochemical impedance spectroscopy (auto) ; lanthanum compounds (auto) ; relaxation (auto) ; solid oxide fuel cells (auto) ; strontium compounds (auto)